LETTER OF INTENTCuris Inc • July 2nd, 2001 • Biological products, (no disgnostic substances)
The Parties intend to enter into two further agreements, a Target Research and License Agreement and a Development Agreement, within the next two weeks (extendible by mutual agreement). Under the Development Agreement, the Parties will jointly develop therapeutic antibody(ies). The agreement may provide either party the option to withdraw from the project at certain agreed time points. In that case, the other party may develop the antibody on its own or with a partner, and the Parties agree that, to the extent possible, all Curis or Micromet Patent Rights relevant to the Therapeutic Antibody will be licensed or sublicensed to the Party continuing development, to the extent necessary for such continued development.
No. 2 STOCK SUBSCRIPTION WARRANTCuris Inc • March 14th, 2000
Exhibit 10.64 PLEDGE AGREEMENT ---------------- This is a pledge agreement made as of the 17th day of June, 1996 between Doros Platika ("Pledgor") and Ontogeny, Inc. ("Pledgee"). 1. Pledge of Collateral. Pledgor hereby grants Pledgee a security...Pledge Agreement • March 14th, 2000 • Curis Inc
AgreementSubscription Agreement • June 2nd, 2000 • Curis Inc • Biological products, (no disgnostic substances) • Massachusetts
Exhibit 10.48 REGISTRATION RIGHTS AGREEMENT This Agreement dated as of July 1, 1996 is entered into by and among Biogen, Inc., a Massachusetts corporation (the "Purchaser") and Ontogeny, Inc., a Delaware corporation (the "Company"). WHEREAS, the...Registration Rights Agreement • April 3rd, 2000 • Curis Inc • Massachusetts
Exhibit 10.32 Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. LICENSE AGREEMENT MICHIGAN FILE [**], [**], [**] & [**] TECHNOLOGY This Agreement is effective as of the 30th...License Agreement • June 2nd, 2000 • Curis Inc • Biological products, (no disgnostic substances)
EXHIBIT 10.01 SECOND AMENDMENT TO LEASE This Second Amendment to Lease (this "Amendment") is executed by and between David E. Clem and David M. Roby, Trustees (the "Landlord") of 21 Erie Realty Trust u/d/t dated May 16, 1996, recorded with the...Lease • August 14th, 2000 • Curis Inc • Biological products, (no disgnostic substances)
CURIS, INC.Severance Agreement • March 29th, 2002 • Curis Inc • Biological products, (no disgnostic substances) • Massachusetts
Exhibit 10.56 THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "1933 ACT"). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED...Warrant Agreement • March 14th, 2000 • Curis Inc • California
No. STOCK SUBSCRIPTION WARRANTCuris Inc • April 3rd, 2000 • Illinois
CURIS, INC.Registration Rights Agreement • August 14th, 2001 • Curis Inc • Biological products, (no disgnostic substances) • New York
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (this "Agreement"), dated as of July 18, 2001, among Curis, Inc., a Delaware corporation (the "Company"), Elan International Services, Ltd., a Bermuda exempted limited liability...Securities Purchase Agreement • August 14th, 2001 • Curis Inc • Biological products, (no disgnostic substances) • New York
CURIS, INC. 25,652,174 Shares of Common Stock (par value $0.01 per share) Underwriting AgreementUnderwriting Agreement • December 10th, 2020 • Curis Inc • Biological products, (no disgnostic substances) • New York
Curis, Inc., a Delaware corporation (the “Company”), proposes to issue and sell, pursuant to the terms of this Underwriting Agreement (the “Agreement”) to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 25,652,174 shares (the “Shares”) of its common stock, par value $0.01 per share (the “Common Stock”). The 25,652,174 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 3,847,826 Shares pursuant to such option are collectively called the “Option Shares.” The Firm Shares and, if and to the extent such option is exercised, the Option Shares, are collectively called the “Offered Shares.” Cantor Fitzgerald & Co. (“Cantor”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 11th, 2020 • Curis Inc • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of June 11, 2020, between Curis, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
AMONGAgreement and Plan of Merger • March 14th, 2000 • Curis Inc • Delaware
Exhibit 10.4 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the "Agreement"), made as of the 1/st/ day of August, 2002, is entered into by and between Curis, Inc., a Delaware corporation (the "Company"), and Christopher U. Missling (the "Employee")....Employment Agreement • November 12th, 2002 • Curis Inc • Biological products, (no disgnostic substances) • Massachusetts
Nonexclusive License 97-107-.MW 11/20/97 LICENSE AGREEMENT Effective as of November 20, 1997 ("Effective Date"), THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, a body having corporate powers under the laws of the State of California...License Agreement • April 3rd, 2000 • Curis Inc • California
or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing...Securities Purchase Agreement • July 6th, 2023 • Curis Inc • Biological products, (no disgnostic substances) • New York
ONTOGENY, INC.Warrant Agreement • March 14th, 2000 • Curis Inc • Illinois
EXHIBIT 10.48 ------------- PURCHASE AGREEMENT THIS AGREEMENT is made as of the __ day of November, 2000, by and among Curis, Inc. (the "Company"), a corporation organized under the laws of the State of Delaware, with its principal offices at 61...Purchase Agreement • November 29th, 2000 • Curis Inc • Biological products, (no disgnostic substances) • New York
CURIS, INC. SALES AGREEMENTSales Agreement • July 2nd, 2015 • Curis Inc • Biological products, (no disgnostic substances) • New York
Exhibit 10.55 THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. THEY MAY NOT BE SOLD. OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL...Warrant Agreement • March 14th, 2000 • Curis Inc • Illinois
b) The Company shall tend to the Employee $100,000, which shall be due and payable on June 30, 1997. Such loan shall bear interest at the minimum applicable federal interest rate for loans of such duration. Such loan shall be secured by a mortgage on...Employment Agreement • March 30th, 2001 • Curis Inc • Biological products, (no disgnostic substances) • Massachusetts
EXCLUSIVE)Patent License Agreement • June 2nd, 2000 • Curis Inc • Biological products, (no disgnostic substances) • Massachusetts
Exhibit 10.65 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. EXCLUSIVE LICENSE AGREEMENT Effective as of November 2, 1998 ("Effective Date"), THE BOARD OF TRUSTEES OF THE...Exclusive License Agreement • June 2nd, 2000 • Curis Inc • Biological products, (no disgnostic substances) • California
COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • February 27th, 2020 • Curis Inc • Biological products, (no disgnostic substances) • Illinois
COMMON STOCK PURCHASE AGREEMENT (the “Agreement”), dated as of February 26, 2020 by and between CURIS, INC., a Delaware corporation (the “Company”), and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (the “Buyer”). Capitalized terms used herein and not otherwise defined herein are defined in Section 10 hereof.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 27th, 2020 • Curis Inc • Biological products, (no disgnostic substances) • Illinois
REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of February 26, 2020, by and between CURIS, INC., a Delaware corporation (the “Company”), and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Common Stock Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
Exhibit 10.2 LEASE TERMINATION AGREEMENT This Lease Termination Agreement (this "Agreement") is executed by and between David E. Clem and David M. Roby, Trustees (the "Landlord") of 21 Erie Realty Trust u/d/t dated May 16, 1996, recorded with the...Lease Termination Agreement • November 12th, 2002 • Curis Inc • Biological products, (no disgnostic substances)
Exhibit 10.45 FIRST AMENDMENT TO SECURED PROMISSORY NOTE This First Amendment to Secured Promissory Note dated August 3, 2001 in the original principal amount of $500,000 executed by Doros Platika (the "Obligor") on behalf of Curis, Inc. (the...Curis Inc • March 29th, 2002 • Biological products, (no disgnostic substances) • Massachusetts
Exhibit 10.1 AMENDMENT TO LEASES Execution Date: August 9, 2002 This Amendment to Lease is made as of the Execution Date first above written by and between FPRP Moulton LLC, a Massachusetts limited liability company, acting as Trustee of Fresh Pond...Curis Inc • November 12th, 2002 • Biological products, (no disgnostic substances)
Exhibit 10.3 AMENDED AND RESTATED SEVERANCE AGREEMENT AND RELEASE This AMENDED AND RESTATED AGREEMENT (the "Agreement") is made by and between Curis, Inc. (the "Company") and Dr. Doros Platika (the "Executive"). All capitalized words and terms used in...Severance Agreement and Release • November 12th, 2002 • Curis Inc • Biological products, (no disgnostic substances) • Massachusetts
CURIS, INC. Common Stock (par value $0.01 per share) At Market Issuance Sales AgreementCuris Inc • June 13th, 2011 • Biological products, (no disgnostic substances) • New York
Curis, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with McNicoll, Lewis & Vlak LLC (“MLV”), as follows:
6,449,288 Shares Warrants to Purchase 1,612,322 Shares CURIS, INC. Common Stock PLACEMENT AGENT AGREEMENTPlacement Agent Agreement • January 22nd, 2010 • Curis Inc • Biological products, (no disgnostic substances) • New York
Exhibit 10.3 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the "Agreement"), made as of the 20th day of September, 2001, is entered into by and between Curis, Inc., a Delaware corporation (the "Company"), and Daniel R. Passeri (the "Employee"). The...Employment Agreement • November 14th, 2001 • Curis Inc • Biological products, (no disgnostic substances) • Massachusetts
Exhibit 10.3 SECURITY AGREEMENT (Pledged Collateral) In consideration of loans heretofore, now, or hereafter made to Curis Inc. (hereinafter called the "Pledgor") by Boston Private Bank & Trust Company (hereinafter called the "Bank"), and to secure...Security Agreement • June 17th, 2002 • Curis Inc • Biological products, (no disgnostic substances) • Massachusetts
In consideration of loans heretofore, now, or hereafter made to Curis Inc. (hereinafter called the "Pledgor") by Boston Private Bank & Trust Company (hereinafter called the "Bank"), and to secure payment of any liability or obligation of the Pledgor to the Bank, direct or indirect, primary or secondary, now existing or hereafter arising including, without limitation, obligations arising pursuant to a certain Loan Agreement dated June 14, 2002, as amended from time to time (the "Loan Agreement") and Pledgor's Secured Term Note in the principal amount of Four Million Six Hundred Ninety-Four Thousand Eight Hundred Four and 11/100ths ($4,694,804.11) Dollars, dated June 14, 2002 in which Bank is the holder (said liabilities and obligations hereby secured being hereinafter called "Obligations"), the Pledgor assigns, transfers and delivers to the Bank the collateral (to the extent of the principal balance of the Obligations) described on Exhibit A attached hereto and made a part hereof, toget
